Restoration of Electrolyte Homeostasis and Microcirculatory Perfusion in End-Stage Renal Disease via Intravenous Oxyhydrogen and Gasotransmitter Nanobubble Therapy Combined with Potassium Titration: A Case Report
Dewi ATK, Hernowo AT · 2025
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In This case suggests that intravenous nanobubble-based HHO and gasotransmitter therapy, when combined with controlled potassium titration, may safely improve clinical and biochemical parameters in CKD-5, laboratory findings showed stabilization of serum potassium (3.95 to 4.25–4.59 mmol/L), reduction in HbA1c (8.1% to 6.69%), and hs-CRP (8.0 to 2.28 mg/L), without adverse events. These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in This case suggests that intravenous nanobubble-based HHO and gasotransmitter therapy, when combined with controlled potassium titration, may safely improve clinical and biochemical parameters in CKD-5. Laboratory findings showed stabilization of serum potassium (3.95 to 4.25–4.59 mmol/L), reduction in HbA1c (8.1% to 6.69%), and hs-CRP (8.0 to 2.28 mg/L), without adverse events.
What the Researchers Studied
The researchers studied This case suggests that intravenous nanobubble-based HHO and gasotransmitter therapy, when combined with controlled potassium titration, may safely improve clinical and biochemical parameters in CKD-5.
What Effects Did Molecular Hydrogen Have?
Laboratory findings showed stabilization of serum potassium (3.95 to 4.25–4.59 mmol/L), reduction in HbA1c (8.1% to 6.69%), and hs-CRP (8.0 to 2.28 mg/L), without adverse events. The authors concluded that this case suggests that intravenous nanobubble-based HHO and gasotransmitter therapy, when combined with controlled potassium titration, may safely improve clinical and biochemical parameters in CKD-5 patients on hemodialysis.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a case report. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as case report with human clinical evidence. The research population or model was This case suggests that intravenous nanobubble-based HHO and gasotransmitter therapy, when combined with controlled potassium titration, may safely improve clinical and biochemical parameters in CKD-5. The reported sample size was 5.
Limitations and Safety
No separate limitations or safety findings were identified in the current-study source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base. The original scholarly source is available at https://europepmc.org/article/PPR/PPR1059282.